Consensus estimates forecast a $0.01 EPS loss and $12.93M revenue for Protalix BioTherapeutics in Q2.
Protalix BioTherapeutics (PLX) will release its Q2 earnings results on August 12 before the market opens. Analysts expect a loss of $0.01 per share and revenue of $12.93M, reflecting a 17.4% year-over-year decline.
Over the past year, PLX has beaten EPS estimates 50% of the time while consistently surpassing revenue expectations. The company has maintained a perfect record for revenue beats in the last four quarters.
No immediate market reaction details were provided ahead of the announcement.